Literature DB >> 1540785

Measurement of human phospholipase A2 in arthritis plasma using a newly developed sandwich ELISA.

G M Smith1, R L Ward, L McGuigan, I A Rajkovic, K F Scott.   

Abstract

A sandwich enzyme-linked immunosorbent assay (ELISA) for human non-pancreatic phospholipase A2 (PLA2) was developed using monoclonal antibodies raised against purified recombinant PLA2. This assay was shown to be specific for human non-pancreatic PLA2, showing no cross-reactivity with human pancreatic PLA2 or with snake venom PLA2 (Crotalus durissus). The immunoassay showed no cross-reactivity with plasma components, and was reproducible and quantitative between 39 pmol and 2.7 nmol PLA2/1. The levels of non-pancreatic PLA2 in the plasma of patients with arthritis was measured using this immunoassay. There were significantly higher levels of PLA2 in patients with rheumatoid arthritis than in those with osteoarthritis or healthy controls. Plasma PLA2 was highest in those patients with active rheumatoid arthritis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1540785     DOI: 10.1093/rheumatology/31.3.175

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  17 in total

1.  Enzymatic activity and immunoreactivity of extracellular phospholipase A2 in inflammatory synovial fluids.

Authors:  W Pruzanski; K Scott; G Smith; I Rajkovic; E Stefanski; P Vadas
Journal:  Inflammation       Date:  1992-10       Impact factor: 4.092

2.  Lysophosphatidylcholines to phosphatidylcholines ratio predicts advanced knee osteoarthritis.

Authors:  Weidong Zhang; Guang Sun; Dawn Aitken; Sergei Likhodii; Ming Liu; Glynn Martin; Andrew Furey; Edward Randell; Proton Rahman; Graeme Jones; Guangju Zhai
Journal:  Rheumatology (Oxford)       Date:  2016-05-09       Impact factor: 7.580

3.  Tenidap sodium decreases renal clearance and increases steady-state concentrations of lithium in healthy volunteers.

Authors:  G Apseloff; K D Wilner; D A von Deutsch; N Gerber
Journal:  Br J Clin Pharmacol       Date:  1995       Impact factor: 4.335

4.  An investigation into the effect of tenidap sodium on the pharmacokinetics of a combined oral contraceptive.

Authors:  P E Coates; R Mesure
Journal:  Br J Clin Pharmacol       Date:  1995       Impact factor: 4.335

5.  Effect of tenidap sodium on the pharmacodynamics and plasma protein binding of warfarin in healthy volunteers.

Authors:  G Apseloff; K D Wilner; N Gerber
Journal:  Br J Clin Pharmacol       Date:  1995       Impact factor: 4.335

6.  Cimetidine does not alter the clearance or plasma binding of tenidap in healthy male volunteers.

Authors:  K D Wilner; M J Gardner
Journal:  Br J Clin Pharmacol       Date:  1995       Impact factor: 4.335

7.  Tenidap sodium does not alter the clearance or plasma protein binding of tolbutamide in healthy male volunteers.

Authors:  K D Wilner; M J Gardner
Journal:  Br J Clin Pharmacol       Date:  1995       Impact factor: 4.335

8.  The effect of tenidap on the anti-hypertensive efficacy of thiazide diuretics in patients treated for mild to moderate hypertension.

Authors:  W G Rapeport; V C Grimwood; K Korlipara; M G Grillage; I James; J L Anderton; D I Selfridge
Journal:  Br J Clin Pharmacol       Date:  1995       Impact factor: 4.335

9.  Selective inhibition of human group IIA-secreted phospholipase A2 (hGIIA) signaling reveals arachidonic acid metabolism is associated with colocalization of hGIIA to vimentin in rheumatoid synoviocytes.

Authors:  Lawrence K Lee; Katherine J Bryant; Romaric Bouveret; Pei-Wen Lei; Anthony P Duff; Stephen J Harrop; Edwin P Huang; Richard P Harvey; Michael H Gelb; Peter P Gray; Paul M Curmi; Anne M Cunningham; W Bret Church; Kieran F Scott
Journal:  J Biol Chem       Date:  2013-03-12       Impact factor: 5.157

10.  Increased expression of human type IIa secretory phospholipase A2 antigen in arthritic synovium.

Authors:  O S Jamal; P G Conaghan; A M Cunningham; P M Brooks; V F Munro; K F Scott
Journal:  Ann Rheum Dis       Date:  1998-09       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.